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short clinical period of fatigue, anemic syndrome and muco-ntroduction
plastic anemia (AA) is a rare disorder characterized by sup-
ression of bone marrow function. It can develop as the
esult of congenital marrow disease and chemical exposure;
owever, most cases are idiopathic.1 Treatment with immuno-
uppressive therapy (IST) for patients who do not have an
uman leukocyte antigen (HLA)-compatible donor relies on
he evidence that a deregulated immune system drives T
ymphocytes to cytokine-mediated destruction of their own
ematopoietic stem cells.1 The majority of these patients
espond well to up-front administration of IST, including anti-
hymocyte globulin (ATG) and cyclosporine (CsA), which is
uccessful in around 80%.2 Unfortunately, ATG and CsA can
ead to clonal disorders, in particular myelodysplastic syn-
rome (MDS) and paroxysmal nocturnal hemoglobinuria.3 OnPlease cite this article in press as: Jaime-Pérez JC, et al. Myelodysplasia a
phamide in a child with severe aplastic anemia. Rev Bras Hematol Hemot
he other hand, high doses of cyclophosphamide (HDCY) have
een administered as a sole immunosuppressive agent in
evere aplastic anemia (SAA), principally in adults, with no
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pen  access article under the CC BY-NC-ND license (http://creativecomlate clonal disorders reported after up to ten years of follow
up.4 However, late complications following HDCY, including
lasting neutropenia and severe fungal infections have been
reported mainly in adults, but no similar late complications
have been reported for patients who received HDCY during
childhood.
We report the ﬁrst case of a boy with SAA treated suc-
cessfully with HDCY who after 15 years developed MDS  that
rapidly evolved into acute myeloid leukemia (AML), and who
was treated unsuccessfully with a hematopoietic stem cell
transplant (HSCT).
Case  report
A ﬁve-year-old boy was diagnosed in 1997 with SAA after and acute myeloid leukemia ﬁfteen years after high-dose cyclophos-
er. 2016. http://dx.doi.org/10.1016/j.bjhh.2016.06.003
, Ediﬁcio “Dr. Rodrigo Barragán”, 2 Piso, Ave. Madero y Gonzalitos
cutaneous bleeding, and ﬁndings consistent with SAA in his
complete blood count (Table 1).1 Bone marrow aspirate (BMA)
and biopsy examinations showed a hypoplastic specimen
 e Terapia Celular. Published by Elsevier Editora Ltda. This is an
mons.org/licenses/by-nc-nd/4.0/).
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Table 1 – Complete blood count at diagnosis, during
myelodysplasia and after progression to acute myeloid
leukemia (AML) of a severe aplastic anemia patient
treated with high-dose cyclophosphamide who  suffered
late clonal evolution after 15 years of follow-up.
SAA MDS AML
Hemoglobin (g/dL) 4.00 7.4 4.88
Hematocrit (%) 11.9 20.8 14.5
MCV (fL) 101 84.6 84.5
RDW (%) 16.2 13.5 11.4
Platelet count (×109/L) 15.0 22.4 6.36
WBC (×109/L) 1.52 2.12 5.47a
Neutrophils (×109/L) 0.36 0.45 0.361
Neutrophils (%) 23.7 21.24 6.60
Lymphocytes (×109/L) 1.05 1.4 1.39
Lymphocytes (%) 69.3 66.01 25.4
SAA: severe aplastic anemia; MDS: myelodysplastic syndrome;
AML: acute myeloid leukemia; MCV: mean corpuscular volume;
RDW: red cell distribution width; WBC: white blood cell count.
hematopoietic regeneration. However, as this case exempli-a 96% myeloid blasts.
without megakaryocytes, with less than 15% cellularity and
no dysplastic changes; cytogenetic studies were not available
in our center at diagnosis. A test for hypersensitivity of Fan-
coni anemia (FA) cells to diepoxybutane, the diepoxybutane
(DEB) test, which helps early diagnosis of FA5 was not per-
formed. The patient had no HLA-compatible donor and, at that
time, therapy with ATG plus CS was not available in our coun-
try. The patient was part of a group of ﬁve children with SAA
treated with HDCY under these circumstances; the results
of that trial have been published.6 The treatment protocol
consisted of cyclophosphamide (CY) at 50 mg/kg/day adminis-
tered intravenously (IV) over 1 h on four consecutive days with
a total dose of 200 mg/kg, plus granulocyte colony stimulat-
ing factor (G-CSF) at 5 g/kg/day, administered subcutaneously
from Day +1 post-HDCY until an absolute neutrophil count
(ANC) >1 × 109/L was reached. The patient achieved complete
hematological remission, and remained free of transfusion
requirements with no infections. No dysplastic or clonal
hematological disorders developed over 15 years of follow-up.
Fifteen years after HDCY, this patient presented with severe
anemia and he was treated with packed red blood cell trans-
fusions, folic acid (5 mg/day) and danazol (200 mg  b.i.d.). Three
months later, classical ﬁndings of myelodysplasia were doc-
umented in peripheral blood and bone marrow, including
hypercellular bone marrow with a signiﬁcant increase in the
number of micromegakaryocytes and reticulin ﬁbrosis Grade
3. Five months later, the MDS  progressed to alpha-naphthyl
butyrate esterase-positive acute myeloblastic leukemia (AML-
M5). The bone marrow immunophenotype demonstrated cells
with CD4, CD11b, CD16, CD36, CD56, CD64, and HLA-DR anti-
genic speciﬁcities.
Important hematologic data at the time of myelodysplasia
and after AML  are shown in Table 1.
Standard AML  chemotherapy was started, including cytara-Please cite this article in press as: Jaime-Pérez JC, et al. Myelodysplasia a
phamide in a child with severe aplastic anemia. Rev Bras Hematol Hemot
bine for seven days plus mitoxantrone for three days. It was
decided to perform haploidentical stem cell transplantation
fourteen days after the diagnosis of AML  because of the per-
sistence of blasts in the peripheral blood and due to the 0 1 6;x  x x(x x):xxx–xxx
background and poor prognosis. A reduced-intensity condi-
tioning (RIC) regimen was administered 45 days after the end
of induction consisting of cyclophosphamide, ﬂudarabine, and
busulfan. Haploidentical HSCT was performed on Day +6 of
conditioning using his mother as donor. He presented neu-
tropenia and fever on the same day as the procedure, and
antibiotics were administered with no improvement. Hema-
turia and melena developed requiring intensive transfusion
support. Pneumonia unresponsive to treatment was followed
by cardiopulmonary arrest and death two days after trans-
plant.
Discussion
The treatment of choice for SAA patients who have a
matched sibling donor is HSCT with survival rates of up
to 90%.1 Front-line matched unrelated donor appears to be
a viable option in children, with similar overall survival
and event-free survival to transplants with matched sibling
donors. A matched unrelated donor HSCT after failure of
IST has proved to be a very good rescue strategy.7 As in
our case, most SAA patients lack a suitable donor and, in
the absence of IST, mortality is 75%.8 Currently, a response
rate of 44–80% with a three- to ﬁve-year survival rate ran-
ging from 81 to 93% for SAA patients immunosuppressed
with ATG plus CsA and granulocyte-colony stimulating fac-
tor (G-CSF) has been reported.2 AA patients, however, can
have a partial response, fail to respond, relapse, or remain
dependent of CsA. In order to circumvent these short-
comings, alternative IST, such as alemtuzumab, as well as
promising agents, including eltrombopag, are currently being
investigated.
Successful immunosuppressive treatment of SAA with
ATG and CsA has been associated with late clonal disor-
ders, including paroxysmal nocturnal hemoglobinuria and
MDS.3 High dose cyclophosphamide has also been success-
fully administered in SAA, mostly in adults, with no such
late clonal disorders reported after a decade of follow up.4
There is however, evidence for late complications follow-
ing HDCY, including lasting neutropenia and severe fungal
infections.4 These adverse long-term events have not been
reported for patients who received HDCY during childhood. A
recent study focusing on the outcomes of pediatric patients
with AA found clonal evolution and disease progression to
MDS in ﬁve patients out of 149 (3%) that had moderate
AA.2 Our patient had a stable course with good quality of
life for 15 years after successful treatment with HDCY; he
then evolved to severe MDS shortly followed by AML, treated
unsuccessfully with chemotherapy and followed by a matched
related donor HSCT that was complicated by sepsis leading to
death.
In conclusion, HDCY for children with SAA who  do not have
a suitable hematopoietic stem cell donor and no access to
standard therapy with ATG plus CsA can lead to long-termnd acute myeloid leukemia ﬁfteen years after high-dose cyclophos-
er. 2016. http://dx.doi.org/10.1016/j.bjhh.2016.06.003
ﬁes for the ﬁrst time in this age group, late clonal evolution
employing high doses of this powerful immunosuppressant
agent can lead to MDS and AML.
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